Is Cullinan Therapeutics, Inc. profitable?

Cullinan Therapeutics, Inc. is not currently profitable: it reported a net loss of $221.0M over the trailing twelve months, a -346.1% net margin.

What is Cullinan Therapeutics, Inc.'s earnings per share?

Cullinan Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.84.

Where does Cullinan Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Cullinan Therapeutics, Inc. CGEM Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Research and development	$42.12M-1.9%	$42.95M+2.3%	$41.97M-31.2%	$61.03M+47.2%	$41.46M+2.4%
General and administrative	$11.57M-6.0%	$12.31M-9.6%	$13.63M-7.7%	$14.77M+9.1%	$13.54M-7.0%
Other operating expenses	$53.7M-2.8%	$55.26M-0.6%	$55.6M-26.7%	$75.8M+37.8%	$55M-0.1%
Total operating expenses	$53.7M-2.8%	$55.26M-0.6%	$55.6M-26.7%	$75.8M+37.8%	$55M-0.1%
Operating income	-$53.7M+2.8%	-$55.26M+0.6%	-$55.6M+26.7%	-$75.8M-37.8%	-$55M+0.1%
Interest income	$4.1M-11.2%	$4.62M-9.4%	$5.09M-14.0%	$5.92M-10.0%	$6.58M-12.4%
Other income (expense), net	-$62K+10.1%	-$69K+36.1%	-$108K+40.3%	-$181K-113%	-$85K—
Net income	-$49.66M+2.1%	-$50.71M-0.2%	-$50.61M+27.8%	-$70.06M-44.4%	-$48.5M-1.8%
Diluted earnings per share	——	——	——	——	——
Basic earnings per share	——	——	——	——	——
Weighted-average shares, diluted	——	——	——	——	——
Weighted-average shares, basic	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	-$50.67M-0.8%	-$50.24M+28.2%	-$69.95M-46.2%	-$47.86M+1.8%
Unrealized gains (losses) on available-for-sale securities	-$893K-2,000%	$47K-87.2%	$366K+259%	$102K-84.0%	$638K+158%
Other income, net (Note 6)	-$62K+10.1%	-$69K+36.1%	-$108K+40.3%	-$181K-113%	-$85K—
EBIT	-$53.7M+2.8%	-$55.26M+0.6%	-$55.6M+26.7%	-$75.8M-37.8%	-$55M+0.1%
EBITDA	-$53.62M+2.8%	-$55.18M+0.6%	-$55.52M+26.7%	-$75.72M-37.9%	-$54.92M+0.1%
EBITDA	-$53.62M+2.8%	-$55.18M+0.6%	-$55.52M+26.7%	-$75.72M-37.9%	-$54.92M+0.1%
EBIT	-$53.7M+2.8%	-$55.26M+0.6%	-$55.6M+26.7%	-$75.8M-37.8%	-$55M+0.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Cullinan Therapeutics, Inc. profitable?: Cullinan Therapeutics, Inc. is not currently profitable: it reported a net loss of $221.0M over the trailing twelve months, a -346.1% net margin.
What is Cullinan Therapeutics, Inc.'s earnings per share?: Cullinan Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.84.
Where does Cullinan Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.